Novartis(US:NVS) Zhi Tong Cai Jing·2026-01-28 13:23Core Viewpoint - Novartis has received approval from the National Medical Products Administration (NMPA) in China for its innovative small interfering RNA cholesterol-lowering drug, inclisiran, which is indicated as an adjunct to diet for adult patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia to lower low-density lipoprotein cholesterol (LDL-C) [1] Group 1 - Inclisiran is the first and currently the only approved small interfering RNA drug targeting PCSK9 for cholesterol reduction globally [1] - The approval expands the treatment options for patients with dyslipidemia, building on previous indications for use with statins or in combination with statins and other lipid-lowering therapies [1] - The biannual dosing regimen of inclisiran is expected to enhance treatment adherence and improve long-term LDL-C target achievement, aiding in the long-term management of lipid levels [1]